A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19

General Information Age Group Adults Status Closed Protocol Number 000110 Background Information Study enrollment complete with topline data expected in April 2021. The purpose of this research study is to evaluate the safety of Fostamatinib in hospitalized patients with COVID-19. This is a randomized, double blind, placebo-controlled trial. Patients will be given Fostamatinib for two weeks, beginning while they are in the hospital and will complete the course at home if discharged prior to the end of the 14 days. Patients will receive study follow up in person or via telephone after discharge at the National Institute of Health. Participation in the study is 60 days from the date of enrollment. Offered At Inova Fairfax Hospital 3300 Gallows Rd. Falls Church, VA 22042 Principal Investigator Steven Nathan, MD Eligibility Information Hospitalized and requiring oxygen at the time of enrollment At least 18 years old Positive COVID-19 test within 7 days Ineligibility Information Elevated Liver Enzymes Decreased Kidney Function Known allergy to study medication Uncontrolled high blood pressure Certain types of infections Certain medications Live vaccine within 4 weeks Contact Information Contact Name Rebecca Hays, RN Contact Phone 703-776-5444 Contact Email Send Email